Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosphenytoin - Pfizer

Drug Profile

Fosphenytoin - Pfizer

Alternative Names: ACC 9653; ACC 9653-010; Cerebyx; Cereneu; Fosphenytoin sodium; Fostoin; NPC-06; PD 135711-15B; Pro-Epanutin; Prodilantin; Prophenytoin

Latest Information Update: 01 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Nobelpharma; Pfizer
  • Class Analgesics; Antiepileptic drugs; Hydantoins; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Phase II Neuropathic pain
  • Discontinued Stroke

Most Recent Events

  • 25 Oct 2019 Nobelpharma plans a phase II trial for Acute pain (Adjunctive treatment) (IV, Infusion) , (NCT04139330)
  • 03 Apr 2019 Phase-II clinical trials in Neuropathic pain (In adolescents, In adults, In the elderly) in Japan (IV) (NCT03773055)
  • 13 Dec 2018 Nobelpharma plans a phase II trial for Neuropathic pain in January 2019 (IV), (NCT03773055)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top